Medi Assist Q1FY26 profit rises 22% on revenue jump

Key takeaway for investors

Medi Assist Healthcare Services Ltd reported a strong start to FY26, posting higher revenue and profit in the quarter ended June 30, 2026. Consolidated net profit rose 21.9% year-on-year (YoY) to ₹275.97 million, supported by a 24% increase in revenue from operations. The company also laid out its near-term results calendar, with the Board scheduled to consider and approve unaudited Q1 FY27 standalone and consolidated results on August 8, 2026, and an earnings call set for August 10, 2026.

Q1FY26: revenue and profit moved higher

For Q1FY26, Medi Assist reported consolidated revenue from operations of ₹2,365.19 million, compared with ₹1,905.58 million in Q1FY25. This translated into a 24% YoY increase in revenue, as cited in the update. Consolidated net profit for the same quarter came in at ₹275.97 million, up from ₹226.31 million a year ago, a rise of 21.9%.

The company also reported an improvement in basic earnings per share (EPS) at the consolidated level. Consolidated basic EPS increased to ₹3.71 in Q1FY26 from ₹3.18 in Q1FY25. The numbers, as presented, indicate that profit growth broadly tracked the revenue increase during the quarter.

Standalone performance also improved

Alongside consolidated performance, Medi Assist disclosed standalone results for Q1FY26. Standalone revenue from operations rose to ₹589.84 million in Q1FY26 from ₹437.04 million in Q1FY25. Standalone net profit increased to ₹131.52 million from ₹80.20 million in the year-ago period.

Standalone basic EPS was reported at ₹1.76 for Q1FY26, compared with ₹1.14 in Q1FY25. The presence of both standalone and consolidated disclosures offers investors a clearer view of performance at the entity level and group level.

Auditor review and compliance notes

The statutory auditors, MSK A & Associates LLP, issued an unmodified review report on the unaudited financial results. The company stated that the results were prepared in accordance with Ind AS 34. It also referenced Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Such statements matter because they set the context for how the quarterly numbers were compiled and reviewed. The update does not describe any qualification or adverse observation, and explicitly notes the review report was unmodified.

Financial snapshot (all amounts normalised to ₹ crore)

Note: Values converted from ₹ million to ₹ crore (₹1 crore = ₹10 million) for consistency.

Q1 FY27 results: board meeting and disclosure schedule

Medi Assist said its Board of Directors is scheduled to meet on Saturday, August 8, 2026. The stated agenda is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, described as Q1 FY27 in the communication.

The company also indicated that the financial results for the quarter are pending board approval. It added that the financial impact will be known after the board meeting on August 8, 2026.

Trading window closure for designated persons

The company disclosed that its trading window is closed for dealing in securities by designated persons and their immediate relatives. The closure period is from July 1, 2026, and will remain closed until 48 hours after the declaration of the financial results.

The disclosure cites the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company’s internal policy. Such trading window announcements are a standard compliance step around results-related disclosures.

Earnings call on August 10: management participation and access

Medi Assist has scheduled an earnings call to discuss the Q1 FY27 financial results on Monday, August 10, 2026 at 8:30 AM IST. The call is set to feature Dr. Vikram Chhatwal, Satish Gidugu, and Sandeep Daga.

For dial-in access, the company listed India operator-assisted numbers as +91 22 6280 1131 and +91 22 7115 8032. It also provided an investor contact email: investor.relations@mediassist.in.

Additional performance context cited in the update

The material also referenced operational and profitability trends from other periods. For Q4FY26, revenue from operations was stated at ₹2,419.86 million, representing 0.96% quarter-on-quarter (QoQ) growth from ₹2,396.78 million and 28.12% YoY growth from ₹1,888.72 million. Total income for Q4FY26 was cited at ₹2,432.32 million.

For FY26, total income was reported at ₹9,232.44 million, up 23.58% YoY compared with ₹7,470.78 million in FY25. The update also mentioned Q4FY26 net profit of ₹544.77 million.

Separately, the text included a quarterly table in crores showing net sales turnover, total income, and reported PAT across recent quarters, including a reported PAT of ₹8.02 crore for Jun’25.

Valuation markers and published estimate ranges

The update included a P/E ratio of 29.9 and noted the stock trading at a P/E of 29.9, along with a market cap of ₹2,875 (unit not specified in the text). It also mentioned a “CMP Rs.363.”

A Q1 FY27 preview section provided estimate ranges: Q1 FY27E revenue of ₹228-262 crore and PAT of ₹30-38 crore, along with a 12-month target range of ₹430-478. The same section stated these estimates were built using a trailing-growth framework applied to a Q1 FY26 base of ₹198 crore revenue and ₹23 crore net profit, using the most recent year-on-year growth signal from Q4 FY26.

Market impact: what to track around the results dates

The disclosed calendar creates two immediate checkpoints for investors: the board approval date on August 8, 2026 and the management discussion on August 10, 2026. In practice, these events often influence near-term trading activity because they concentrate information flow into a narrow window.

The trading window closure from July 1, 2026 until 48 hours after results declaration also signals that the company is in a results-sensitive period. For the market, the key driver will be the Q1 FY27 numbers once approved and released, since the company explicitly stated the financial impact will be known after the board meeting.

Analysis: why the Q1FY26 print and Q1FY27 schedule matter

The Q1FY26 results show revenue expansion and profit growth moving in the same direction, with consolidated profit up 21.9% and revenue up 24% YoY. This alignment is important because it indicates the profit uplift was not solely the result of one-off effects in the reported period, based on the limited data shared.

The unmodified limited review report and the stated compliance with Ind AS 34 and SEBI LODR Regulation 33 are also relevant for investors evaluating disclosure quality. Meanwhile, the presence of published estimate ranges for Q1 FY27 and a stated CMP provides context for how some market participants may frame expectations into the August 8 result date.

Key dates table

Conclusion

Medi Assist’s Q1FY26 results showed a 21.9% YoY rise in consolidated net profit to ₹27.60 crore and a 24% increase in revenue to ₹236.52 crore. The next confirmed catalyst is the Board meeting on August 8, 2026 to consider and approve Q1 FY27 results, followed by the earnings call on August 10, 2026 at 8:30 AM IST.